Article Text

Download PDFPDF

Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required
  1. Robert J Moots,
  2. Alejandro Balsa,
  3. Gertjan Wolbink
  1. University of Liverpool, Liverpool, UK
  1. Correspondence to Professor Robert J Moots, University of Liverpool, Liverpool, UK; rjmoots{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We welcome the study from Emery et al1 reporting the phase III trial comparing the biosimilar SB4 with originator etanercept. In this publication, the authors report comparable clinical efficacy and safety profile between both drugs, but an apparent difference in immunogenicity, with ‘antidrug antibodies (ADAs)’ reported in only 0.7% of patients taking SB4, compared with 13% with reference product, etanercept.

While the development of ADAs clearly has the potential to translate into the …

View Full Text

Linked Articles